Healthcare ranking
Top 10 IgA nephropathy clinical trial sponsors 2026
Jiangsu Hengrui Pharmaceuticals started the most IgA nephropathy clinical trials as lead sponsor between November 2023 and October 2026, with 7 trials. The list ranks companies worldwide by the number of new interventional trials they lead in this area.
Top 10 at a glance
The full list
| Rank | Company | Headquarters | new industry-sponsored clinical trials (trials) |
|---|---|---|---|
| 1 | Jiangsu Hengrui Pharmaceuticals | China | 7 |
| 2 | Novartis | Switzerland | 5 |
| 3 | Haisco Pharmaceutical Group | China | 3 |
| 3 | Shanghai Fosun Pharmaceutical | China | 3 |
| 3 | Vertex Pharmaceuticals | United States | 3 |
| 3 | Vera Therapeutics | United States | 3 |
| 7 | AstraZeneca | United Kingdom | 2 |
| 7 | Hansoh Pharmaceutical | China | 2 |
| 7 | Otsuka | Japan | 2 |
| 7 | Rigerna Therapeutics | China | 2 |
| 7 | ADARx Pharmaceuticals | United States | 2 |
| 7 | Biohaven Therapeutics | United States | 2 |
How this list is built
We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list IgA nephropathy as a studied condition; withdrawn trials are not counted. Subsidiaries and name variants are merged into the parent company ("Chengdu Suncadia Medicine Co., Ltd." and "Guangdong Hengrui Pharmaceutical Co., Ltd" are counted as Jiangsu Hengrui Pharmaceuticals), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.
Every position is set by the data alone, by the same rules for every company. Spotted something to update? Write to info@stratummarketresearch.com with the list and the line, and we correct it within two working days.
For ranked companies: a free badge
Ranked companies can show this badge on their website, in a press release or on LinkedIn at no cost. Pick your company, then copy the code.
Frequently asked questions
Who is number one in the igA nephropathy clinical trial sponsors ranking?
Jiangsu Hengrui Pharmaceuticals ranks first with 7 trials (November 2023 to October 2026).
How is this ranking calculated?
We counted interventional clinical trials with a company as lead sponsor and a start date from 1 November 2023 to 31 October 2026 that list IgA nephropathy as a studied condition; withdrawn trials are not counted. Subsidiaries and name variants are merged into the parent company ("Chengdu Suncadia Medicine Co., Ltd." and "Guangdong Hengrui Pharmaceutical Co., Ltd" are counted as Jiangsu Hengrui Pharmaceuticals), and hospitals, universities and other non-company sponsors are left out. Companies with the same count share a rank, and all companies tied at the last place are shown.
Can a company pay to rank higher?
Positions come only from the counts described above, and inclusion is free. Every company is ranked by the same rules.
How often is the ranking updated?
Every list is recomputed each quarter from the latest public records, and the update date is printed on the page.
Can a ranked company use the badge?
Yes. Every ranked company can use the free web badge on this page on its website, in press releases and on social media.
Custom research
Looking for a specific market?
Tell us the market, the region and the decision you are making. We reply within one working day with a scope and a date.